Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings. The ...

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.